Syndicate content

Archive - Jan 24, 2012

Date

Promising New Target Identified for Anti-Hepatitis C Therapy

A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago (UIC) College of Medicine. The cholesterol receptor offers a promising new target for anti-viral therapy, for which an approved drug may already exist, say the researchers, whose findings were reported online on January 8, 2012 in Nature Medicine. An estimated 4.1 million Americans are infected with hepatitis C virus (HCV), which attacks the liver and leads to inflammation, according to the National Institutes of Health. Most people have no symptoms initially and may not know they have the infection until liver damage shows up decades later during routine medical tests. Previous studies showed that cholesterol was somehow involved in HCV infection. The UIC researchers suspected that a receptor called NPC1L1 (Niemann-Pick C1–like 1) cholesterol absorption receptor, known to help maintain cholesterol balance, might also be transporting the virus into the cell. The receptor is common in the gut of many species -- but is found on liver cells only in humans and chimpanzees, says Dr. Susan Uprichard, assistant professor in medicine and microbiology and immunology and principal investigator in the study. These primates, she said, are the only animals that can be infected by HCV. Dr. Uprichard and her coworkers showed that knocking down or blocking access to the NPC1L1 receptor prevented the virus from entering and infecting cells. Dr. Bruno Sainz, Jr., UIC postdoctoral research associate in medicine and first author of the paper, said that because the receptor is involved in cholesterol metabolism it was already well-studied.